Rhythm Pharmaceuticals Announces Topline Results from Phase 3 EMANATE Trial

Core Insights - Rhythm Pharmaceuticals announced topline results from its EMANATE trial, indicating that four substudies did not meet their primary endpoints [1][2] - Despite the disappointing primary results, the company noted encouraging signals from additional analyses of specific substudies, which may inform future development of next-generation MC4R agonists [2][4] Study Overview - EMANATE was a global, randomized, double-blind, placebo-controlled Phase 3 trial designed to evaluate the efficacy and safety of setmelanotide in patients with rare, genetically-driven obesities of the MC4R pathway [2][3] - The trial included four independent genetic substudies focusing on patients with obesity due to heterozygous variants of the POMC/PCSK1, LEPR, SRC1, and SH2B1 genes [2] Topline Results - The primary endpoint was the difference in mean percent change in BMI from baseline to Week 52 versus placebo [3] - Post hoc analyses showed statistically significant and clinically meaningful BMI reductions at Week 52 in the POMC/PCSK1 Hets and SRC1 substudies [3][4] - Specific results included a 5.5% least-squares mean difference in BMI for POMC/PCSK1 Hets patients and a 6.2% difference for SRC1 patients, both statistically significant [5] Safety Profile - No new safety signals were observed with setmelanotide, and the safety profile was consistent with prior studies [3] - Common treatment-emergent adverse events included skin hyperpigmentation, injection site reactions, nausea, vomiting, and headache [3][20] Future Plans - The company plans to continue analyzing the EMANATE dataset and evaluate potential clinical development paths for SRC1 and POMC with next-generation MC4R agonists [4][6] - Rhythm is also advancing a broad clinical development program for setmelanotide and investigational MC4R agonists [9]